Dr Andtbacka meets with ecancertv at WCCS 2016 to discuss the use of oncolytic virotherapy (OV) in the treatment of melanoma.
He discusses the OPTiM trials of T-VEC, a genetically modified herpes virus, including identifying which patients have the most durable response, and looks forward to potential combinations for T-VEC and other OVs.
For more on oncolytic virotherapy, you can read a brief history here.
ecancer's filming at WCCS 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.